Drug Profile
Levamlodipine/valsartan - Hanlim Pharmaceutical
Alternative Names: Lodivixx; S-amlodipine nicotinate/valsartan; Valsartan/levamlodipine; Valsartan/S-amlodipine nicotinateLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Hanlim Pharmaceutical
- Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Nicotinic acids; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 27 Aug 2018 Hanlim Pharm. completes a phase I trial in Healthy volunteers in August 2018 (NCT03648333)
- 31 Mar 2013 Hanlim Pharmaceutical initiates a phase I trial in healthy volunteers in South Korea (NCT01819779)
- 31 Dec 2012 Hanlim Pharmaceutical completes a phase I pharmacokinetics trial in healthy volunteers in South Korea (NCT01652339)